HEC-1-B

HEC-1-B/HEC-1-B细胞系/HEC-1-B细胞株/HEC-1-B人子宫内膜癌细胞

Cell line name HEC-1-B

Synonyms Hec-1-B; HEC-1B; Hec-1b; HEC1-B; HEC1B; Hec1B

Accession CVCL_0294

Resource Identification Initiative To cite this cell line use: HEC-1-B (RRID:CVCL_0294)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: MD Anderson Cell Lines Project.

Population: Japanese.

Microsatellite instability: Instable (MSI) (PubMed=31068700).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.

PubMed=833871; DOI=10.1093/jnci/58.2.209

Fogh J., Wright W.C., Loveless J.D.

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

J. Natl. Cancer Inst. 58:209-214(1977)

 

PubMed=6163305

Sekiya S., Takamizawa H.

Effect of anticancer drugs on in vitro survival of cell lines derived from various gynecologic tumors.

Nihon Sanka Fujinka Gakkai Zasshi 33:373-376(1981)

 

PubMed=6174649

Sekiya S., Kawata M., Inaba N., Takamizawa H.

Studies on marker substances in cell lines derived from various human gynecologic tumors.

Nihon Sanka Fujinka Gakkai Zasshi 34:37-42(1982)

 

PubMed=6220172

Dracopoli N.C., Fogh J.

Polymorphic enzyme analysis of cultured human tumor cell lines.

J. Natl. Cancer Inst. 70:469-476(1983)

 

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

 

PubMed=12227503; DOI=10.1111/j.1749-0774.2002.tb00103.x

Kuramoto H., Hamano M., Imai M.

HEC-1 cells.

Hum. Cell 15:81-95(2002)

 

DOI=10.1007/978-4-431-53981-0_1

Kuramoto H., Hamano M., Imai M., Fujisawa T., Kamata Y., Arai T., Kawaguchi M.

HEC-1 cells: establishment of an in vitro experimental system in endometrial carcinoma.

(In book chapter) Cell and molecular biology of endometrial carcinoma; Kuramoto H., Nishida M. (eds.); pp.3-34; Springer; Tokyo; Japan (2003)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=20218740; DOI=10.1177/153303461000900207; PMCID=PMC5120669

Wang Y.-M., Yang D., Cogdell D., Hu L.-M., Xue F.-X., Broaddus R., Zhang W.

Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma.

Technol. Cancer Res. Treat. 9:179-189(2010)

 

PubMed=20944090; DOI=10.1126/scitranslmed.3001538

Dedes K.J., Wetterskog D., Mendes-Pereira A.M., Natrajan R., Lambros M.B., Geyer F.C., Vatcheva R., Savage K., Mackay A., Lord C.J., Ashworth A., Reis-Filho J.S.

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.

Sci. Transl. Med. 2:53ra75.1-53ra75.8(2010)